TY - JOUR
T1 - Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer
AU - Burford, B.
AU - Gentry-Maharaj, A.
AU - Graham, R.
AU - Allen, D.
AU - Pedersen, J. W.
AU - Nudelman, A. S.
AU - Blixt, O.
AU - Fourkala, E. O.
AU - Bueti, D.
AU - Dawnay, A.
AU - Ford, J.
AU - Desai, R.
AU - David, L.
AU - Trinder, P.
AU - Acres, B.
AU - Schwientek, T.
AU - Gammerman, A.
AU - Reis, C. A.
AU - Silva, L.
AU - Osório, H.
AU - Hallett, R.
AU - Wandall, H. H.
AU - Mandel, U.
AU - Hollingsworth, M. A.
AU - Jacobs, I.
AU - Fentiman, I.
AU - Clausen, H.
AU - Taylor-Papadimitriou, J.
AU - Menon, U.
AU - Burchell, J. M.
N1 - Funding Information:
We are particularly grateful to women who contributed their samples to this study and to the medical, nursing and administrative staff who worked on the UKCTOCS/ Guernsey study. UKCTOCS was core funded by the Medical Research Council, Cancer Research UK and the NIHR with additional support from the Eve Appeal, Special Trustees of Bart’s and the London and Special Trustees of UCLH. This study was supported by an EU FP7 collaborative project grant, O-PTM Biomarkers, grant agreement number 201381 and NIH grant U01CA128437-03. We also acknowledge financial support from the Experimental Cancer Medicine Centre at King’s College London and the National Institute for Health Research via CBRC funding (women’s health theme) to University College London Hospitals (UCLH) in partnership with University College London, and the Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. We also acknowledge financial support from the Excellence programme at University of Copenhagen, the Danish Research Council and National Research Foundation. The researchers are independent from the funders and the views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. UKCTOCS was core funded by the Medical Research Council, Cancer Research UK, and the NIHR with additional support from the Eve Appeal, Special Trustees of Bart’s and the London, and Special Trustees of UCLH.
PY - 2013/5
Y1 - 2013/5
N2 - Background:Autoantibodies have been detected in sera before diagnosis of cancer leading to interest in their potential as screening/early detection biomarkers. As we have found autoantibodies to MUC1 glycopeptides to be elevated in early-stage breast cancer patients, in this study we analysed these autoantibodies in large population cohorts of sera taken before cancer diagnosis.Methods:Serum samples from women who subsequently developed breast cancer, and aged-matched controls, were identified from UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and Guernsey serum banks to formed discovery and validation sets. These were screened on a microarray platform of 60mer MUC1 glycopeptides and recombinant MUC1 containing 16 tandem repeats. Additional case-control sets comprised of women who subsequently developed ovarian, pancreatic and lung cancer were also screened on the arrays.Results:In the discovery (273 cases, 273 controls) and the two validation sets (UKCTOCS 426 cases, 426 controls; Guernsey 303 cases and 606 controls), no differences were found in autoantibody reactivity to MUC1 tandem repeat peptide or glycoforms between cases and controls. Furthermore, no differences were observed between ovarian, pancreatic and lung cancer cases and controls.Conclusion:This robust, validated study shows autoantibodies to MUC1 peptide or glycopeptides cannot be used for breast, ovarian, lung or pancreatic cancer screening. This has significant implications for research on the use of MUC1 in cancer detection.
AB - Background:Autoantibodies have been detected in sera before diagnosis of cancer leading to interest in their potential as screening/early detection biomarkers. As we have found autoantibodies to MUC1 glycopeptides to be elevated in early-stage breast cancer patients, in this study we analysed these autoantibodies in large population cohorts of sera taken before cancer diagnosis.Methods:Serum samples from women who subsequently developed breast cancer, and aged-matched controls, were identified from UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and Guernsey serum banks to formed discovery and validation sets. These were screened on a microarray platform of 60mer MUC1 glycopeptides and recombinant MUC1 containing 16 tandem repeats. Additional case-control sets comprised of women who subsequently developed ovarian, pancreatic and lung cancer were also screened on the arrays.Results:In the discovery (273 cases, 273 controls) and the two validation sets (UKCTOCS 426 cases, 426 controls; Guernsey 303 cases and 606 controls), no differences were found in autoantibody reactivity to MUC1 tandem repeat peptide or glycoforms between cases and controls. Furthermore, no differences were observed between ovarian, pancreatic and lung cancer cases and controls.Conclusion:This robust, validated study shows autoantibodies to MUC1 peptide or glycopeptides cannot be used for breast, ovarian, lung or pancreatic cancer screening. This has significant implications for research on the use of MUC1 in cancer detection.
UR - http://www.scopus.com/inward/record.url?scp=84878554709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878554709&partnerID=8YFLogxK
U2 - 10.1038/bjc.2013.214
DO - 10.1038/bjc.2013.214
M3 - Article
C2 - 23652307
AN - SCOPUS:84878554709
SN - 0007-0920
VL - 108
SP - 2045
EP - 2055
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 10
ER -